FI93843B - Menetelmä angiogeenisen tekijän tuottamiseksi - Google Patents

Menetelmä angiogeenisen tekijän tuottamiseksi

Info

Publication number
FI93843B
FI93843B FI882891A FI882891A FI93843B FI 93843 B FI93843 B FI 93843B FI 882891 A FI882891 A FI 882891A FI 882891 A FI882891 A FI 882891A FI 93843 B FI93843 B FI 93843B
Authority
FI
Finland
Prior art keywords
angiogenic factor
purified
activity
disclosed
human placental
Prior art date
Application number
FI882891A
Other languages
English (en)
Swedish (sv)
Other versions
FI93843C (fi
FI882891A0 (fi
FI882891A (fi
Inventor
David A Moscatelli
Daniel B Rifkin
Andreas Sommer
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI93843(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synergen Inc filed Critical Synergen Inc
Publication of FI882891A0 publication Critical patent/FI882891A0/fi
Publication of FI882891A publication Critical patent/FI882891A/fi
Application granted granted Critical
Publication of FI93843B publication Critical patent/FI93843B/fi
Publication of FI93843C publication Critical patent/FI93843C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI882891A 1985-12-17 1988-06-16 Menetelmä angiogeenisen tekijän tuottamiseksi FI93843C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80987385A 1985-12-17 1985-12-17
US88855486A 1986-07-16 1986-07-16
US89582986A 1986-08-12 1986-08-12
PCT/US1986/002669 WO1987003885A1 (en) 1985-12-17 1986-12-12 Human placenta angiogenic factor capable of stimulating capillary endothelial cell protease synthesis, dna synthesis and migration

Publications (4)

Publication Number Publication Date
FI882891A0 FI882891A0 (fi) 1988-06-16
FI882891A FI882891A (fi) 1988-06-16
FI93843B true FI93843B (fi) 1995-02-28
FI93843C FI93843C (fi) 1995-06-12

Family

ID=27420052

Family Applications (1)

Application Number Title Priority Date Filing Date
FI882891A FI93843C (fi) 1985-12-17 1988-06-16 Menetelmä angiogeenisen tekijän tuottamiseksi

Country Status (15)

Country Link
EP (1) EP0226181B1 (fi)
JP (1) JPH10262668A (fi)
KR (1) KR960015442B1 (fi)
AT (1) ATE107315T1 (fi)
AU (2) AU6774887A (fi)
DE (1) DE3689921T2 (fi)
DK (1) DK424387D0 (fi)
ES (1) ES2056787T3 (fi)
FI (1) FI93843C (fi)
IE (1) IE863281L (fi)
IL (1) IL80944A (fi)
NO (1) NO177859C (fi)
NZ (1) NZ218631A (fi)
PT (1) PT83939B (fi)
WO (1) WO1987003885A1 (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
CA2002261A1 (en) * 1988-11-07 1990-05-07 Andreas Sommer High molecular weight human angiogenic factors
HUT67217A (en) * 1992-02-14 1995-03-28 Kaken Pharma Co Ltd Remedy for airway diseases
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU2003242459B2 (en) 2002-06-18 2007-05-17 Eisai R&D Management Co., Ltd. Primary cultured adipocytes for gene therapy
US8182840B2 (en) * 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
CN111100191A (zh) * 2018-10-26 2020-05-05 神威药业集团有限公司 源于人胎盘的活性蛋白质或多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209587A (en) * 1978-12-29 1980-06-24 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4225670A (en) * 1978-12-29 1980-09-30 Monsanto Company Production of tumor angiogenesis factor by cell culture
DE3110560A1 (de) * 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
GB2146523B (en) * 1983-09-13 1987-01-07 Ward Page Faulk Preparation for stimulating growth of blood vessels prepared from amniochorionic tissue and macrophages
ATE105868T1 (de) * 1985-09-12 1994-06-15 Scios Nova Inc Rekombinanter fibroblast-wachstumsfaktor.
IL81650A0 (en) * 1986-02-24 1987-09-16 Robapharm Ag Purified human angiogenic factor,method for its preparation and pharmaceutical preparations

Also Published As

Publication number Publication date
NO873437L (no) 1987-08-14
JPH10262668A (ja) 1998-10-06
DE3689921D1 (de) 1994-07-21
PT83939A (en) 1987-01-01
EP0226181A2 (en) 1987-06-24
NO177859C (no) 1995-12-06
FI93843C (fi) 1995-06-12
IL80944A0 (en) 1987-03-31
KR960015442B1 (ko) 1996-11-14
IE863281L (en) 1987-06-17
DK424387A (da) 1987-08-14
ES2056787T3 (es) 1994-10-16
AU7629991A (en) 1991-08-08
IL80944A (en) 1994-10-07
EP0226181A3 (en) 1989-03-08
ATE107315T1 (de) 1994-07-15
WO1987003885A1 (en) 1987-07-02
AU6774887A (en) 1987-07-15
DE3689921T2 (de) 1994-09-22
FI882891A0 (fi) 1988-06-16
NO177859B (no) 1995-08-28
FI882891A (fi) 1988-06-16
AU650649B2 (en) 1994-06-30
DK424387D0 (da) 1987-08-14
KR880700820A (ko) 1988-04-12
EP0226181B1 (en) 1994-06-15
NZ218631A (en) 1991-07-26
PT83939B (pt) 1989-05-31
NO873437D0 (no) 1987-08-14

Similar Documents

Publication Publication Date Title
NO177678C (no) Fremgangsmåte for fremstilling av et terapeutisk aktivt, rekombinant protein som har ASP-aktivitet, ekspresjonssystem samt DNA som koder for nevnte protein
DK0751992T3 (da) Karendotelvækstfaktor 2
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DK151985A (da) Humant fysiologisk aktivt polypeptid
DE3873397D1 (de) Bifunktionelle proteine.
DK193887D0 (da) Fysiologisk aktivt peptid
NZ209590A (en) Gamma interferon analogue, preparation and pharmaceutical composition
FI93843B (fi) Menetelmä angiogeenisen tekijän tuottamiseksi
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DK288789A (da) Peptider og syreadditionssalte deraf, deres fremstilling og anvendelse
DK229387A (da) Retinoesyreestere, deres fremstilling og farmaceutiske og kosmetiske praeparater deraf
KR900005994A (ko) 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
IT1217314B (it) Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
EP0272894A3 (en) Recombinant human lymphotoxin
PT85226A (en) Process for the preparation of novel trombolytic proteins
IT8349430A0 (it) Metodo per la produzione di proteine antigeniche specifiche del virusdell'epatite umana a, loro utilizzazione per la produzione di preparazioni farmaceutiche e mezzi diagnostici

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: SYNERGEN, INC.